76 related articles for article (PubMed ID: 21050135)
1. A morphological screening of protein crystals for interferon delivery by metal ion-chelate technology.
Jiang Y; Shi K; Wang S; Li X; Cui F
Drug Dev Ind Pharm; 2010 Dec; 36(12):1389-97. PubMed ID: 21050135
[TBL] [Abstract][Full Text] [Related]
2. Protamine modified metal ion-protein chelate microparticles for sustained release of interferon.
Jiang Y; Shi K; Xia D; Piao H; Quan P; Song T; Cui F
Int J Pharm; 2011 Apr; 407(1-2):31-7. PubMed ID: 21220001
[TBL] [Abstract][Full Text] [Related]
3. Protein spherulites for sustained release of interferon: preparation, characterization and in vivo evaluation.
Jiang Y; Shi K; Xia D; Wang S; Song T; Cui F
J Pharm Sci; 2011 May; 100(5):1913-22. PubMed ID: 21374623
[TBL] [Abstract][Full Text] [Related]
4. [Self-assembly and in vitro and in vivo evaluation of spherical crystallized interferon for sustained delivery].
Shi K; Cui FD; Bi HS; Jiang YB
Yao Xue Xue Bao; 2013 Aug; 48(8):1333-7. PubMed ID: 24187845
[TBL] [Abstract][Full Text] [Related]
5. Long-term stabilization of a new freeze-dried and albumin-free formulation of recombinant human interferon alpha 2b.
Ruiz L; Reyes N; Sotolongo J; Aroche K; Aldana R; Báez R; Hardy E
PDA J Pharm Sci Technol; 2006; 60(1):72-8. PubMed ID: 17089680
[TBL] [Abstract][Full Text] [Related]
6. Multivesicular liposome formulations for the sustained delivery of interferon alpha-2b.
Qiu J; Wei XH; Geng F; Liu R; Zhang JW; Xu YH
Acta Pharmacol Sin; 2005 Nov; 26(11):1395-401. PubMed ID: 16225764
[TBL] [Abstract][Full Text] [Related]
7. Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin.
Ruiz L; Reyes N; Duany L; Franco A; Aroche K; Hardy Rando E
Int J Pharm; 2003 Oct; 264(1-2):57-72. PubMed ID: 12972336
[TBL] [Abstract][Full Text] [Related]
8. Production, purification, and chemical stability of recombinant human interferon-γ in low oxygen tension condition: a formulation approach.
Malek-Sabet N; Masoumian MR; Zeinali M; Khalilzadeh R; Mousaabadi JM
Prep Biochem Biotechnol; 2013; 43(6):586-600. PubMed ID: 23742090
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting the in vitro release of recombinant human interferon-gamma (rhIFN-gamma) from PLGA microspheres.
Yang J; Cleland JL
J Pharm Sci; 1997 Aug; 86(8):908-14. PubMed ID: 9269868
[TBL] [Abstract][Full Text] [Related]
10. Metal ions guided self-assembly of therapeutic proteins for controllable release: from random to ordered aggregation.
Shi K; Cui F; Bi H; Jiang Y; Shi H; Song T
Pharm Res; 2013 Jan; 30(1):269-79. PubMed ID: 22975806
[TBL] [Abstract][Full Text] [Related]
11. [Obtaining and characteristics of domestic preparation interferon alpha-2b with prolonged effect].
Pokholenko IaA; Porubleva LV; Dubeĭ IIa; Rebriev AV; Sutugina LP; Gromovoĭ TIu; Pokrovskiĭ VA; Obolenskaia MIu; Chernykh SI
Ukr Biokhim Zh (1999); 2008; 80(6):92-100. PubMed ID: 19351063
[TBL] [Abstract][Full Text] [Related]
12. A novel method to prepare highly encapsulated interferon-alpha-2b containing liposomes for intramuscular sustained release.
Yang L; Yang W; Bi D; Zeng Q
Eur J Pharm Biopharm; 2006 Aug; 64(1):9-15. PubMed ID: 16797953
[TBL] [Abstract][Full Text] [Related]
13. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
[TBL] [Abstract][Full Text] [Related]
14. Molecular and Biological Characterization of a Prepared Recombinant Human Interferon Alpha 2b Isoform.
Shaaban R; El-Sayed WM; Samir S; El-Dabaa E
Appl Biochem Biotechnol; 2019 May; 188(1):72-86. PubMed ID: 30334171
[TBL] [Abstract][Full Text] [Related]
15. [Pegylated interferons: pharmacological basis].
Macquin-Mavier I; Hezode C; Dhumeaux D
Gastroenterol Clin Biol; 2002; 26(8-9):742-7. PubMed ID: 12434079
[No Abstract] [Full Text] [Related]
16. Some factors affecting the stability of interferon alpha 2b in solution.
Ruiz L; Reyes N; Aroche K; Báez R; Aldana R; Hardy E
Biologicals; 2006 Mar; 34(1):15-9. PubMed ID: 16188456
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions.
Yanai Y; Sanou O; Kayano T; Ariyasu H; Yamamoto K; Yamauchi H; Ikegami H; Kurimoto M
J Interferon Cytokine Res; 2001 Oct; 21(10):835-41. PubMed ID: 11710996
[TBL] [Abstract][Full Text] [Related]
18. Preparation of CHO cell-derived rhIFN-ω-Fc with improved pharmacokinetics.
Li J; Li B; Zhang J; Hou L; Yu C; Fu L; Song X; Yu T; Zhang J; Ren J; Xu C; Chen W
Antiviral Res; 2011 Mar; 89(3):199-203. PubMed ID: 21277904
[TBL] [Abstract][Full Text] [Related]
19. Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs.
Yuan L; Wang J; Shen WC
J Control Release; 2008 Jul; 129(1):11-7. PubMed ID: 18448186
[TBL] [Abstract][Full Text] [Related]
20. Antiviral activity of rChIFN-α against vesicular stomatitis virus and Newcastle disease virus: a novel recombinant chicken interferon-α showed high antiviral activity.
Hou F; Liu K; Shen T; Zhou B; Cao R; Li P; Chen P
Res Vet Sci; 2011 Dec; 91(3):e73-9. PubMed ID: 21196022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
